Differential metabolites in cirrhotic patients with hepatitis B and muscle mass loss

Xuechun Liu, Lei Han, Shenghua Bi, Xueli Ding, Quan Z. Sheng, Yueping Jiang, Ge Guan, Qinghui Niu, Jing XueFrontiers in Nutrition 2023 · DOI

This study, published in Frontiers in Nutrition, investigates the metabolic "fingerprint" of muscle mass loss (sarcopenia) in patients suffering from hepatitis B virus (HBV)-related cirrhosis. By identifying 11 specific biomarkers in the blood, the researchers provide a potential roadmap for earlier diagnosis and targeted nutritional interventions to improve survival in these high-risk patients.

TL;DR

Researchers used GC-MS metabolomics to identify 70 distinct metabolites that differentiate cirrhotic patients with muscle loss from those without it. They pinpointed 11 high-accuracy biomarkers, including inosine-5′-monophosphate and (r)-3-hydroxybutyric acid, suggesting that amino acid and central carbon metabolism are the primary drivers of muscle depletion in HBV-related cirrhosis.

What Problem Does This Paper Address?

Sarcopenia—the progressive loss of muscle mass and function—is a silent killer in patients with liver cirrhosis, affecting 40–70% of the population. It is strongly associated with complications like infections, hepatic encephalopathy, and poor overall survival.

While the metabolic changes associated with alcoholic and non-alcoholic fatty liver disease (NASH) are well-documented, the specific metabolic profile of muscle loss in HBV-related decompensated cirrhosis remained a gap in the literature. Understanding these chemical shifts is crucial for developing diagnostic tools and "gut-liver-muscle axis" therapies that go beyond simple high-protein diets.

Methods

The researchers conducted a cross-sectional study with 60 participants divided into three equal groups:

  1. Group S: HBV-related cirrhosis with muscle mass loss.
  2. Group NS: HBV-related cirrhosis with normal muscle mass.
  3. Group H: Healthy controls.

Key Techniques: * Imaging (SMI): To define muscle loss, the team used the "gold standard": CT scans at the third lumbar vertebra (L3) to calculate the Skeletal Muscle Index (SMI). * Metabolomics: Fasting plasma samples were analyzed using Gas Chromatography–Mass Spectrometry (GC–MS). * Bioinformatics: They employed unsupervised Principal Component Analysis (PCA) to see broad groupings and supervised Orthogonal Partial Least-Squares Discriminant Analysis (OPLS-DA) to filter out noise and identify the most significant metabolites. * Validation: Receiver Operating Characteristic (ROC) curves were used to determine the diagnostic accuracy (AUC) of potential biomarkers.

Datasets

The study utilized a primary clinical dataset of 60 patients recruited from the Affiliated Hospital of Qingdao University between 2021 and 2022. While no external large-scale datasets were used for training, the metabolic products were cross-referenced and confirmed using the Kyoto Encyclopedia of Genes and Genomes (KEGG) database to map biological pathways.

Key Insights and Ideas

  • The Metabolic Signature: The study identified 70 differential metabolites between patients with and without muscle loss. Most were organic acids, lipids, and organic oxygen compounds.
  • The "Hub" Metabolites: L-glutamic acid and L-tyrosine appeared in almost all enriched pathways, suggesting they act as metabolic "hubs" for the processes leading to muscle wasting.
  • The IMP Connection: Inosine-5′-monophosphate (IMP), which is vital for energy availability and protein synthesis, was significantly downregulated in the muscle loss group. The authors suggest IMP could be a future candidate for dietary supplementation.
  • Counter-intuitive Creatinine: Interestingly, creatinine levels were higher in the muscle loss group (Group S). While creatinine usually scales with muscle mass in healthy people, in this diseased state, it likely reflects increased muscle breakdown (creatine phosphate degradation) rather than total mass.

Key Results

  • Biomarker Accuracy: 11 metabolites showed strong predictive value (AUC > 0.7). The top performers were:
  • Inosine-5′-monophosphate: AUC = 0.9825
    • Phosphoglycolic acid: AUC = 0.975
    • D-fructose-6-phosphate: AUC = 0.95
  • Pathway Disruption: 25 metabolic pathways were significantly disturbed. The most impacted were amino acid metabolism and central carbon metabolism in cancer.
  • Ketone Bodies: (r)-3-hydroxybutyric acid was significantly increased in Group S, suggesting a shift in how the body attempts to generate energy when standard glucose/protein metabolism fails.

Limitations and Future Work

  • Sample Size: With only 20 patients per group, this is a relatively small, single-center study. The results need validation in larger, multi-ethnic cohorts.
  • Mass vs. Function: The study focused strictly on muscle mass (quantity) via imaging. It did not measure muscle strength or function (quality), which are also critical components of the clinical definition of sarcopenia.
  • BCAA Gap: The researchers noted they did not specifically screen for branched-chain amino acids (BCAAs), which are known to improve muscle mass in cirrhosis, leaving a potential area for more granular future research.
  • Causality: As a cross-sectional study, it identifies correlations. Longitudinal studies are needed to determine if these metabolic changes cause muscle loss or are merely a byproduct of it.

Summary updated

Abstract

Seventy differential metabolites were identified in patients who have liver cirrhosis and loss of muscle mass compared with patients who have cirrhosis and normal muscle mass. Certain biomarkers might distinguish between muscle mass loss and normal muscle mass in HBV-related cirrhosis patients.
BibTeX
@inproceedings{liu2023differential,
  author = {Xuechun Liu and Lei Han and Shenghua Bi and Xueli Ding and Quan Z. Sheng and Yueping Jiang and Ge Guan and Qinghui Niu and Jing Xue},
  title = {{Differential metabolites in cirrhotic patients with hepatitis B and muscle mass loss}},
  booktitle = {Frontiers in Nutrition},
  year = {2023},
  doi = {10.3389/fnut.2023.1068779},
}
Figure